Lexapro birth defects lawsuits have resulted in significant legal action against Forest Laboratories (now part of Allergan), with the company paying $313 million in 2010 to resolve criminal charges and False Claims Act allegations related to illegal marketing of Lexapro and Celexa for pediatric use. Families who gave birth to children with congenital defects after taking Lexapro during pregnancy have pursued individual and class action claims, with related settlements in multidistrict litigation reaching between $7.7 and $10.4 million. The FDA’s 2011 safety update formally linked the SSRI antidepressant to birth defects including persistent pulmonary hypertension of the newborn (PPHN), providing scientific backing for these legal claims.
While the major waves of Lexapro birth defect litigation appear to have passed””with MDL-2067 closing in August 2018″”individuals who believe they were harmed may still pursue claims. Some law firms indicate they are no longer actively seeking new Lexapro cases but continue working on existing ones. For context, GlaxoSmithKline has settled over 800 birth defect cases involving Paxil, another SSRI, paying approximately $1.2 million per case, which illustrates the substantial compensation that successful SSRI birth defect claims can achieve. This article covers the scientific evidence behind these lawsuits, the history of litigation and settlements, who may qualify to file a claim, and the current status of Lexapro-related legal action.
Table of Contents
- What Evidence Links Lexapro to Birth Defects in Lawsuits?
- History of Lexapro Litigation and Major Settlements
- Who Qualifies to File a Lexapro Birth Defect Claim?
- Comparing Lexapro Settlements to Other SSRI Birth Defect Cases
- Challenges and Limitations in Lexapro Birth Defect Cases
- The Role of the FDA’s 2011 Safety Update
- Current Status and Future Outlook for Lexapro Claims
- Conclusion
What Evidence Links Lexapro to Birth Defects in Lawsuits?
The foundation for Lexapro birth defect lawsuits rests on substantial scientific research and regulatory action. A 2006 study published in the New England Journal of Medicine found a six-fold increase in persistent pulmonary hypertension of the newborn (PPHN) among children exposed to SSRI antidepressants in the womb. This condition prevents newborns from breathing properly and can be life-threatening. The FDA responded by categorizing Lexapro as a Pregnancy Category C drug, indicating an increased risk for congenital birth defects when taken during pregnancy.
The National Birth Defects Prevention Study expanded on these findings, identifying links between SSRI use during the first trimester and several serious conditions: omphalocele (intestines protruding outside the body), craniosynostosis (premature fusion of skull bones), anencephaly (severe brain underdevelopment), and heart defects including atrial and ventricular septal defects. In December 2011, the FDA released a formal safety update specifically linking Lexapro to these congenital birth defects. However, it’s important to note that Pregnancy Category C does not mean the drug definitively causes harm in all cases””it indicates that animal studies have shown adverse effects and there are no adequate human studies, or that no animal studies have been conducted. This nuance matters in litigation because defendants often argue that the statistical association does not prove causation in any individual case.
History of Lexapro Litigation and Major Settlements
The largest financial resolution involving Lexapro came in September 2010, when Forest Pharmaceuticals pleaded guilty and paid $313 million to resolve criminal charges and False Claims Act allegations. The company had illegally marketed Celexa and Lexapro for pediatric use despite lacking FDA approval for that population. Of this settlement, over $88 million went to the federal government, more than $60 million was distributed to states, and approximately $14 million went to whistleblowers who exposed the company’s practices. Birth defect-specific litigation followed. In 2012, three mothers filed lawsuits in St.
Louis against Forest Laboratories alleging that Lexapro use during pregnancy caused limb defects and other congenital abnormalities in their children. These cases joined a broader wave of litigation that had been building since 2006. mdl-1736 consolidated 57 Celexa and Lexapro lawsuits between 2006 and 2013, with most cases settling for undisclosed amounts. A separate class action, MDL-2067, resulted in a settlement of $7.7 to $10.4 million paid by Forest Laboratories to Missouri parents who had purchased Celexa or Lexapro for minors. Individual claimants who could not verify their purchase amounts received $50 each. This MDL closed in August 2018, marking the end of the consolidated litigation process.
Who Qualifies to File a Lexapro Birth Defect Claim?
Potential claimants in Lexapro birth defect lawsuits typically must demonstrate that the mother took Lexapro during pregnancy””particularly during the first trimester when major organ systems develop””and that the child was born with one of the defects linked to SSRI exposure. These include PPHN, heart defects such as septal abnormalities, cranial malformations, and limb defects. Medical records documenting both the prescription history and the diagnosis are essential. However, if a child’s defect has another identifiable cause””such as genetic conditions, other medications, or environmental factors””the case becomes significantly more difficult to prove.
Defense attorneys routinely argue that the plaintiff cannot establish that Lexapro, rather than some other factor, caused the specific birth defect. Cases where the mother took multiple medications during pregnancy face additional challenges in establishing which drug was responsible. The statute of limitations for filing a claim varies by state and typically begins either at the time of injury (birth) or when the plaintiff discovered or should have discovered the connection between the drug and the injury. Given that the major litigation waves occurred between 2006 and 2018, individuals considering new claims should consult with an attorney immediately to determine whether the filing deadline has passed in their jurisdiction.
Comparing Lexapro Settlements to Other SSRI Birth Defect Cases
Lexapro settlements provide useful context when compared to litigation involving other SSRI antidepressants. GlaxoSmithKline, the manufacturer of Paxil, has settled over 800 birth defect cases, paying approximately $1.2 million per case. The company also settled Paxil suicide and attempted suicide cases for $390 million total. These figures suggest that individual birth defect claims, when successful, can result in substantial compensation. The difference in settlement values between Lexapro and Paxil cases likely reflects several factors.
Paxil was introduced earlier and had a longer track record of documented problems before Lexapro entered the market. Forest Laboratories also faced the $313 million illegal marketing settlement, which addressed some corporate misconduct claims that might otherwise have been raised in individual cases. Additionally, the timing of FDA warnings and the strength of scientific evidence available at the time of each drug’s peak litigation affected case outcomes. For families weighing whether to pursue a claim, these comparisons illustrate that compensation is possible but varies significantly based on the strength of evidence, the severity of the child’s condition, and the jurisdiction where the case is filed. Settlement amounts in consolidated litigation are often lower per claimant than verdicts in individual trials, but settlements provide certainty while trials carry the risk of receiving nothing.
Challenges and Limitations in Lexapro Birth Defect Cases
Proving causation remains the central challenge in any pharmaceutical birth defect case. While studies show a statistical association between SSRI use and certain defects, defense teams argue that association does not equal causation in any individual case. Birth defects occur in approximately three percent of all pregnancies regardless of medication use, and defendants point to this baseline rate when challenging plaintiff claims. The black box warning now carried by Lexapro has complicated litigation in another way. This warning, the FDA’s most serious label alert, informs patients and doctors of the known risks.
Defendants argue that once adequate warnings exist, patients who continue taking the medication assume the risk. Cases involving pregnancies that occurred after the black box warning was added face this “learned intermediary” defense, where the manufacturer claims it properly warned the prescribing physician. Some law firms have stopped actively seeking new Lexapro birth defect cases, though they continue working on existing matters. This shift suggests that the legal landscape has changed””whether due to the warnings, the passage of time, or the completion of major litigation. Individuals who believe they have a valid claim should not assume the door is closed, but they should be prepared for attorneys to carefully evaluate case viability before accepting new clients.
The Role of the FDA’s 2011 Safety Update
The FDA’s December 2011 safety update specifically linking Lexapro to congenital birth defects marked a turning point in the litigation. Before this announcement, plaintiffs had to rely primarily on independent studies and expert testimony to establish the drug’s dangers.
The FDA’s formal acknowledgment provided official validation that strengthened existing cases and encouraged new filings. The update specifically addressed persistent pulmonary hypertension of the newborn, a serious condition that had been identified in the 2006 New England Journal of Medicine study. By formally recognizing this link five years after the initial research, the FDA gave plaintiffs a powerful piece of evidence: a federal agency had reviewed the science and concluded the risk was real enough to warrant a public warning.
Current Status and Future Outlook for Lexapro Claims
As of 2025-2026, no major new Lexapro-specific birth defect settlements or verdicts have been publicly reported. The consolidated litigation in MDL-2067 closed in August 2018, and the intense period of filing new claims has passed. This does not mean litigation has ended entirely, but the pharmaceutical defendant’s primary legal exposure appears to have been addressed through prior settlements.
For individuals whose children suffered birth defects potentially linked to Lexapro, the path forward depends on timing and circumstances. Those with strong evidence and claims within the statute of limitations may still find attorneys willing to pursue their cases, particularly if the defects are severe and the mother’s Lexapro use during pregnancy is well-documented. However, expectations should be tempered by the reality that the legal environment has shifted and many firms have moved their resources to newer pharmaceutical litigation.
Conclusion
Lexapro birth defects lawsuits achieved significant results during their peak litigation period, including the $313 million settlement for illegal marketing and millions more in class action resolutions. The scientific evidence linking SSRI antidepressants to conditions like PPHN, heart defects, and other congenital abnormalities provided the foundation for these claims, with the FDA’s 2011 safety update offering official confirmation of the risks.
While the major waves of litigation have concluded, individuals who believe their children were harmed by Lexapro during pregnancy should consult with a qualified attorney to evaluate their specific situation. Statute of limitations concerns make prompt action essential. The comparison to Paxil settlements, where individual birth defect cases settled for approximately $1.2 million each, demonstrates that substantial compensation remains possible in well-documented cases””though the legal landscape continues to evolve.